IN8BIO Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, reported its third quarter 2025 financial results and recent business highlights. For the quarter ended September 30, 2025, research and development (R&D) expenses were $2.1 million, down from $3.3 million for the same period in the prior year. This decrease was primarily attributed to a strategic pause in clinical trial-related activities for the INB-400 program and personnel-related costs following pipeline prioritization announced in September 2024. Non-cash items such as stock-based compensation and depreciation accounted for $0.5 million of the R&D expenses. IN8BIO also presented new preclinical data on INB-619, its CD19 targeting gamma-delta T cell engager, at the 2025 American College of Rheumatology $(ACR)$ Convergence Meeting. In preclinical systemic lupus erythematosus models, INB-619 demonstrated complete B cell elimination with potency equivalent to commercial CD19 and CD20 engagers, including FDA-approved blinatumomab and mosunetuzumab, and showed minimal adverse cytokine release. The company expanded its Phase 1 INB-100 trial to The James Comprehensive Cancer Center at The Ohio State University to support faster enrollment and announced that updated clinical data for the INB-200/400 program in newly diagnosed glioblastoma will be presented at the 2025 Society for Neuro-Oncology Annual Meeting. IN8BIO continues to prioritize programs with the strongest clinical signals and commercial opportunities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570851-en) on November 06, 2025, and is solely responsible for the information contained therein.
Comments